Treatment of CNS germinoma with chemotherapy and radiotherapy

Treatment of CNS germinoma using chemotherapy followed by reduced dose radiotherapy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

CRIS

Registry ID

KCT0005442

Enrollment

Registered

2020-09-25

Start date

2021-01-05

Completion date

Unknown

Last updated

2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug, Radiation : 1. Chemotherapy A regimen (CE): carboplatin 450 mg/m^2/day (d0), etoposide 150 mg/m^2/day (d0-2) B regimen (ECy): etoposide 150 mg/m^2/day (d0-2), cyclophosphamide 1,000 mg/m^2/

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Pathologically proven CNS germinoma 2) Age: 3-30 years 3) Normal plasma and CSF aFP 4) Plasma and CSF b-hCG < 200 mIU/ml 5) Patients with informed consent

Exclusion criteria

Exclusion criteria: 1) Patients with organ dysfunction as follows - Serum Cr > 1.5 x ULN or creatinine clearance = 30 mL/min - Cardiac ejection fraction <40% or severe arrhythmia or conduction disorder 2) Other sever mediacal illness which makes scheduled treatment impossible 3) Pregnant or nursing women 4) Patients with a past history of severe hypersensitivity to clinical trial drugs 5) Patients who are currently using pentostatin

Design outcomes

Primary

Measure	Time frame
Rate of event free survival	—

Secondary

Measure	Time frame
Rate of late adverse effects	—

Countries

Korea, Republic of

Contacts

Public ContactJi Won Lee

Samsung Medical Center

agnesjw@hanmail.net+82-2-3410-0659

Outcome results